1 Many patients with severe and persistent mental illness have not had a trial of the new antipsychotic medications, including Clozaril.
These patients may continue to demonstrate both positive and negative symptoms of psychiatric illness and consequently remain at risk for the consequences of psychotic illnesses, including the significant risk of suicide. 2Families and clinicians are often frustrated by the lack of efficacious treatment for patients with serious and persistent mental illness, but lack a simple tool to engage in conversations with prescribing clinicians regarding more optimal antipsychotic medication treatment. 3The Levels of Recovery From Psychotic Illness Chart can be used successfully with patients, families, and staff to optimize antipsychotic medication trials, including Clozaril.
Mots-clés Pascal : Organisation santé, Santé mentale, Traitement, Chimiothérapie, Psychose, Clozapine, Neuroleptique, Psychotrope, Etats Unis, Amérique du Nord, Amérique, Homme, Dibenzodiazépine
Mots-clés Pascal anglais : Public health organization, Mental health, Treatment, Chemotherapy, Psychosis, Clozapine, Neuroleptic, Psychotropic, United States, North America, America, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0043292
Code Inist : 002B18H05B. Création : 31/05/1999.